WO2010113225A1 - Riluzole-containing transdermal patch - Google Patents

Riluzole-containing transdermal patch Download PDF

Info

Publication number
WO2010113225A1
WO2010113225A1 PCT/JP2009/004320 JP2009004320W WO2010113225A1 WO 2010113225 A1 WO2010113225 A1 WO 2010113225A1 JP 2009004320 W JP2009004320 W JP 2009004320W WO 2010113225 A1 WO2010113225 A1 WO 2010113225A1
Authority
WO
WIPO (PCT)
Prior art keywords
drug
riluzole
patch
transdermal patch
containing layer
Prior art date
Application number
PCT/JP2009/004320
Other languages
French (fr)
Inventor
Makoto Yoshitake
Koutarou Ga
Original Assignee
Yutoku Pharmaceutical Industries Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yutoku Pharmaceutical Industries Co., Ltd. filed Critical Yutoku Pharmaceutical Industries Co., Ltd.
Publication of WO2010113225A1 publication Critical patent/WO2010113225A1/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches

Definitions

  • This invention relates to a transdermal patch comprising a backing layer, a drug-containing layer and a release liner, and containing riluzole in the drug-containing layer as an active ingredient.
  • ALS Amyotrophic lateral sclerosis
  • ventral horn motor neuron and cortex neuron which provides afferent inputs, and is known as the fatal disease by causing pneumonia or respiratory insufficiency to many patients in two to three years.
  • the currently available and sole cure for ALS is an oral drug under the name of "Rilutek (registered trademark) tablet” containing riluzole as an active ingredient.
  • Patent Literature 1 discloses a composition containing riluzole such as cream for the production of a drug for the treatment of the diseases characterized by the hyperproliferation of keratinocytes, particularly psoriasis and atopic dermatitis.
  • This Patent Literature 1 discloses that the cream is a transdermal formulation for the topical administration of riluzole on the skin and the like, and is useful for the treatment and/or prevention of other diseases such as ALS where high plasma concentration is necessary.
  • an appropriate amount of riluzole should be transdermally administered in consideration of the occurrence of the adverse effects in case that the drugs are administered to the ALS patients for the treatment of ALS, the control of the dose and the plasma concentration by the cream are difficult.
  • the object of the present invention is to provide a new transdermal formulation containing riluzole which is capable of the administration to the patients who have difficulties with the oral administration, and is able to inhibit the adverse effects caused by the oral administration and to improve the difficulty of the control of the dose and the plasma concentration caused by the cream described in Patent Literature 1. Furthermore, the another object of the present invention is to provide the transdermal formulation by which high transdermal absorption of riluzole can be achieved and the compliance and quality of life (QOL) of the patients can be improved.
  • QOL quality of life
  • the present inventors have found that providing the transdermal patch containing riluzole can solve the above-mentioned problems and have completed the present invention.
  • the present invention relates to the transdermal patch comprising a backing layer, a drug-containing layer and a release liner, and containing riluzole in the drug-containing layer as the active ingredient.
  • transdermal patches are adopted as the dosage form of riluzole and these patches are adhered on the skin of the ALS patients, and thereby the transdermal administration of riluzole can be achieved to the ALS patients who have difficulties taking the drug orally.
  • the advantage of the transdermal patches of the present invention can be illustrated that the administration amount of riluzole and the plasma concentration can be controlled, and moreover when the undesired effects have occurred, the administration can be immediately discontinued by removing the patches. Consequently, the transdermal patches of the present invention are superior in view of the safety.
  • Fig. 1 is a graph exhibiting the human plasma concentration profiles of riluzole of the patches of Examples 1, 2 and 4 which are calculated by using SKIN-CAD (registered trademark), simulation software for the transdermal system.
  • Fig. 2 is a graph exhibiting the human plasma concentration profiles of riluzole of the patches of Examples13, 16 and 17 which are calculated by using SKIN-CAD (registered trademark), simulation software for the transdermal system.
  • the transdermal patches of the present invention comprise of the drug-containing layer on the backing layer and the drug-containing layer contains riluzole as the active ingredient. Further, a release liner is coated on the drug-containing layer for the purpose of the protection of the drug-containing layer till it uses.
  • transdermal patches of the present invention contain a high concentration of riluzole in the drug-containing layer in order that the effective amount of riluzole for the treatment of ALS is administered transdermally to ALS patients.
  • the transdermal patch is a medicated adhesive patch that is placed on the skin to deliver a specific dose of drug through the skin and into the bloodstream.
  • the amount of riluzole of the transdermal patches of the present invention ranges from 20 to 60% by weight based on the drug-containing layer, preferably from 30 to 60% by weight.
  • the case that the amount is less than 20% by weight is not preferable because the effective plasma concentration is not achieved, and the case that the amount is more than 60% by weight is not preferable because the physical or mechanical properties of the patches difficultly maintain satisfactory.
  • Riluzole which is contained in the transdermal patches of the present invention can be used as a pharmaceutically acceptable salt thereof.
  • the pharmaceutically acceptable salts of riluzole include acid addition salts with inorganic acids or organic acids, and are exemplified, but not limited to, hydrochloride, hydrobromide, nitrate, phosphate, sulfate, acetate, ascorbate, benzoate, cinnamate, citrate, formate, fumarate, glutamate, lactate, maleate, malate, malonate, mandelate, methanesulfonate (mesylate), phthalate, salicylate, stearate, succinate, tartarate, propionate, butyrate, pamoate, p-toluenesulfonate (tosylate) and the like.
  • the area of the transdermal patches of the present invention may ranges from 15 to 60 cm 2 .
  • the case when the area is less than 15 cm 2 is not preferable because the effective plasma concentration is not attained and the case when the area is more than 60 cm 2 is not preferable since the patients feel uncomfortably during the administration and the compliance of the patients is lowered.
  • the transdermal patches of the present invention comprise the backing layer, the drug-containing layer and the release liner.
  • the release-control membranes to control the transdermal absorption of riluzole or the adhesive layers to adhere to the skin can be added, if desired.
  • the reservoir-type patches can be adopted.
  • the drug-containing layer preferably is a matrix-type adhesive layer containing riluzole and an adhesive agent as a base agent.
  • the patches of the present invention can be easily designed and the additional layer such as the adhesive layers is not needed so that the cost for manufacturing the patches can be reduced.
  • the adhesive agents contained in the drug-containing layers of the transdermal patches of the present invention are preferably the non-aqueous adhesive agents, and are inclusive of rubber adhesive agents, acryl polymers and silicone polymers.
  • the rubber adhesive agents are inclusive of one or not less than two agents selected from styrene-isoprene-styrene block copolymer, styrene-butadiene-styrene block copolymer, styrene-butadiene rubber, polyisobutylene, polybutene, butyl rubber, natural rubber and isoprene rubber and can be used in the present invention.
  • the acryl polymers include, but not limited to, the polymers or copolymers containing at least one kind of the (meth)acrylate represented by 2-ethylhexyl acrylate, methyl acrylate, butyl acrylate, 2-hydroxyethyl acrylate, 2-ethylhexyl methacrylate and the like as a monomer unit, for example, adhesive polymers such as acrylic acid-octyl acetate copolymer, 2-ethylhexyl acrylate-N-vinyl-2-pyrrolidone-1,6-hexaneglycolyl dimethacrylate copolymer, 2-ethylhexyl acrylate-vinyl acetate copolymer, 2-ethylhexyl acrylate-vinyl acetate-acrylic acid copolymer, 2-ethylhexyl acrylate-2-ethylhexyl methacrylate-dodecyl meth
  • the silicone polymers include derivatives of polysiloxane (for example, silicone polymer such as polydimethylsiloxane and amine-resistant polydimethylsiloxane).
  • the amount of the adhesive agents added in the drug-containing layer ranges from 20 to 80% by weight, preferably from 35 to 75% by weight in consideration of the formation of the drug-containing layer and the sufficient drug flux.
  • One kind, or two or more kinds in combination selected from the above-mentioned rubber adhesive agents, acryl polymers and silicone polymers can be used as the adhesive agents which are contained in the drug-containing layer of the transdermal patches of the present invention.
  • the acryl polymer can be preferably used in view that riluzole can be contained in a high concentration, and further the high concentration of riluzole can exist in a dissolved state in the drug-containing layer.
  • a non-dissolved riluzole, namely crystalline riluzole which is contained or formed in the drug-containing layer is not preferable because it may cause many troubles such as a drop of the flux of riluzole and an increased formation of the crystalline riluzole with a passage of time.
  • a skin-penetration enhancer can be added, if necessary.
  • the skin-penetration enhancers are inclusive of any agents exhibiting skin-penetration enhancing effects which are conventionally used, and are exemplified an alkanolamine such as diisopropanolamine and triisopropanolamine; a fatty acid or an ester thereof such as lauric acid, oleic acid, isopropyl myristate, octyldodecyl myristate, glycerin monooleate and hexadecyl isostearate; an alcohol, an ester thereof or an ether thereof such as oleyl alcohol, propyleneglycol and polyethyleneglycol monooleate; a sorbitan ester or ether such as sorbitan monolaurate and sorbitan monooleate; a phenol ether such as polyoxyethylene nony
  • an alkanolamine such as diisopropanolamine and triisopropanolamine
  • a myristic acid ester such as isopropyl myristate, octyldodecyl myristate or hexadecyl isostearate
  • propyleneglycol polyoxyethylene lauryl ether or polyoxyethylene oleyl ether are preferable.
  • the amount of the skin-penetration enhancer may ranges from 0.1 to 10% by weight, preferably from 1 to 5% by weight based on the drug-containing layer. Moreover, the contents which exceed 10% by weight are not preferable since the skin irritation caused by the skin-penetration enhancers is used to develop and further the physical properties of the patches are lowered and sticky sense is generated.
  • An additional agent such as a plasticizer, an antioxidant, a cross-linker, a colorant, an ultraviolet ray absorbent, or a tackifier and the like can be blended to the transdermal patches of the present invention, if necessary.
  • the plasticizers include a petroleum oil such as paraffinic process oil, naphthenic process oil and aromatic process oil; a liquid fatty acid ester such as isopropyl myristate, hexyl laurate, diethyl sebacate, diisopropyl sebacate and isopropyl linoleate; a plant oil such as olive oil, camellia oil, castor oil, tall oil and peanut oil; glycerin; chlorobutanol; polyvinyl acetate; dimethylpolysiloxane-silicon dioxide mixture; d-sorbitol; medium chain fatty acid triglyceride; triacetin; 2-pyrrolidone; phytosterol; propylene glycol; polyethylene glycol; polysorbate 80 (registered trademark); and glyceryl monostearate.
  • a petroleum oil such as paraffinic process oil, naphthenic process oil and aromatic process oil
  • a liquid fatty acid ester such as isoprop
  • the antioxidants include ascorbic acid, sodium bisulfite, sodium pyrosulfite, disodium edetate, citric acid, potassium dichloroisocyanurate, dibutylhydroxytoluene, soybean lecithin, thymol, tocopherol or ester thereof, ascorbic acid palmitate, butylhydroxyanisol, 1,3-butylene glycol, benzotriazole, pentaerythrityl-tetrakis[3-(3,5- di-t-butyl-4-hydroxyphenyl)propionate], monothioglycerol, and propyl gallate.
  • the cross-linkers include amino resin; phenolic resin; epoxy resin; alkyd resin; a thermosetting resin such as unsaturated polyester; isocyanate compound; organic cross-linker; and an inorganic cross-linker such as metal or metal compound.
  • the colorants include indigocarmine, yellow oxide of iron, yellow ferric oxide, carbon black, caramel, photosensitizer 201, sasa albo-marginata extract, black iron oxide, kekketsu, zinc oxide, titanium oxide, red ferric oxide, amaranth, sodium hydroxide, talc, sodium copper chlorophyllin, rye green leaf juice powder, d-borneol, 2-octyldodecyl myristate, methylrosanilinium chloride, methylene blue, ammonium manganese phosphate, and rose oil.
  • the ultraviolet ray absorbents include an amino acid compound such as urocanic acid; a benzophenone compound such as 2,4-dihydroxybenzophenone and 2-hydroxy-4-n-octoxybenzophenone; a cinnamic acid derivative such as cinoxate and diethanolamine-p-methoxycinnamate; a cyanoacrylate derivative such as 2-ethylhexyl-2-cyano-3,3-diphenylacrylate; an aminobenzoic acid derivative such as ethyl p-aminobenzoate and propyl p-aminobenzoate; an anthranilic acid derivative such as anthranilic acid and menthyl anthranilate; a salicylate derivative such as phenyl salicylate and p-octylphenyl salicylate; and a coumarin derivative such as 7-ethylamino-4-methylcoumarin and 7,8-dihydroxy coumarin.
  • the tackifiers include a rosin derivative such as rosin, glycerol ester of rosin, hydrogenated rosin and glycerol ester of hydrogenated rosin; alicyclic saturated hydrocarbon resin; alicyclic hydrocarbon resin; terpene resin; aliphatic saturated hydrocarbon resin; aliphatic hydrocarbon resin; maleic acid resin; carnauba wax; carmellose sodium; xanthan gum; chitosan; glycerin; aluminum magnesium silicate; light anhydrous silicic acid; benzyl acetate; talc; hydroxyethylcellulose; hydroxypropylcellulose; hypromellose; polyacrylic acid; sodium polyacrylate; partially neutralized polyacrylate; and polyvinyl alcohol.
  • a rosin derivative such as rosin, glycerol ester of rosin, hydrogenated rosin and glycerol ester of hydrogenated rosin
  • alicyclic saturated hydrocarbon resin such as
  • the drug-impermeable elastic or non-elastic backing can be used as the backing of the transdermal patches of the present invention.
  • Such backings include, for example, synthetic resin film or sheet such as polyethylene, polypropylene, polybutadiene, ethylene vinyl acetate copolymer, polyvinyl chloride, polyester (e.g. polyethylene terephthalate), nylon, polyurethane, or laminates thereof, porous materials and foam thereof, paper, textiles and nonwovens and the like.
  • the drug-impermeable release liner can be used as the release liner of the transdermal patches of the present invention.
  • Such liners are, for example, inclusive of films made of polymer such as polyethylene, polypropylene and polyester and the like, aluminum evaporated film, silicone oil and the like applied paper and the like.
  • polyester film is preferable and polyethylene terephthalate (PET) film is more preferable in view of impermeability of the drug, processability and low cost and the like.
  • PET polyethylene terephthalate
  • laminate films laminated by multiple materials can be used as such release liner.
  • the transdermal patches of the present invention can be prepared, but not limited to, by the known methods.
  • the preferable known methods for preparing the transdermal patches of the present invention include, for example, the method for obtaining the transdermal patches by dissolving the agents such as riluzole and the adhesive polymers and, if necessary, the skin-penetration enhancer to be added to the drug-containing layer into an organic solvent such as ethyl acetate, hexane, toluene or a mixture thereof, spreading these dissolved materials on the release liner or the backing, and evaporating the solvent in the dissolved materials to form the drug-containing layer and thereafter coating on the backing or the release liner, or the method for obtaining the transdermal patches by heating and melting the agents such as riluzole and the adhesive polymers and, if necessary, the skin-penetration enhancer to be added to the drug-containing layer, spreading the melted materials on the release liner or the backing to form the drug-containing layer and thereafter coating on
  • Example 1 According to the ratio of blend described in Table 1, to an acrylic polymer (DURO-TACK (registered trademark) 87-4098, available from Henkle Japan Ltd.) riluzole was added, and mixed with stirring to obtain the homogeneous dissolved mixture. Then the homogeneous dissolved mixture was spreaded on a release liner (silicone-treated PET film, available from Fujimori Kogyo Co., Ltd.) to and the solvent was distilled off to form the drug-containing layer and then the backing was coated. Then, the transdermal patches were obtained by cutting into an appropriate size.
  • DURO-TACK registered trademark
  • 87-4098 acrylic polymer
  • riluzole riluzole was added, and mixed with stirring to obtain the homogeneous dissolved mixture. Then the homogeneous dissolved mixture was spreaded on a release liner (silicone-treated PET film, available from Fujimori Kogyo Co., Ltd.) to and the solvent was distilled off to
  • Example 2 According to the ratio of blend described in Table 1, to an acrylic polymer (DURO-TACK (registered trademark) 87-4098), riluzole and diisopropanolamine were added, and mixed with stirring to obtain the homogeneous dissolved mixture. Then the homogeneous dissolved mixture was spreaded on a release liner (silicone-treated PET containing material after distilling off the solvent by using a doctor blade coater, and the solvent was distilled off to form the drug-containing layer and then the backing was coated. Then, the transdermal patches were obtained by cutting into an appropriate size.
  • a release liner silicone-treated PET containing material after distilling off the solvent by using a doctor blade coater
  • Example 3 According to the ratio of blend described in Table 1, the transdermal patches were obtained by a similar manner as Example 2 except that triisopropanolamine in place of diisopropanolamine was used.
  • Example 4 According to the ratio of blend described in Table 1, the transdermal patches were obtained by a similar manner as Example 2 except that propyleneglycol in place of diisopropanolamine was used.
  • Example 5 According to the ratio of blend described in Table 1, the transdermal patches were obtained by a similar manner as Example 2 except that isopropyl myristate in place of diisopropanolamine was used.
  • Example 6 According to the ratio of blend described in Table 1, the transdermal patches were obtained by a similar manner as Example 2 except that octyldodecyl myristate in place of diisopropanolamine was used.
  • Example 7 According to the ratio of blend described in Table 1, the transdermal patches were obtained by a similar manner as Example 2 except that polyoxyethylene lauryl ether in place of diisopropanolamine was used.
  • Example 8 According to the ratio of blend described in Table 1, the transdermal patches were obtained by a similar manner as Example 2 except that polyoxyethylene oleyl ether in place of diisopropanolamine was used.
  • Example 9 According to the ratio of blend described in Table 1, the transdermal patches were obtained by a similar manner as Example 2 except that DURO-TACK (registered trademark) 87-202A (available from Henkle Japan Ltd.) in place of DURO-TACK (registered trademark) 87-4098 was used.
  • DURO-TACK registered trademark
  • 87-202A available from Henkle Japan Ltd.
  • Example 10 According to the ratio of blend described in Table 1, the transdermal patches were obtained by a similar manner as Example 2 except that DURO-TACK (registered trademark) 87-2100 (available from Henkle Japan Ltd.) in place of DURO-TACK (registered trademark) 87-4098 was used.
  • DURO-TACK registered trademark
  • 87-2100 available from Henkle Japan Ltd.
  • DURO-TACK registered trademark
  • Example 11 According to the ratio of blend described in Table 2, the transdermal patches were obtained by a similar manner as Example 2 except that DURO-TACK (registered trademark) 87-2516 (available from Henkle Japan Ltd.) in place of DURO-TACK (registered trademark) 87-4098 was used.
  • DURO-TACK registered trademark
  • 87-2516 available from Henkle Japan Ltd.
  • DURO-TACK registered trademark
  • Example 12 According to the ratio of blend described in Table 2, the transdermal patches were obtained by a similar manner as Example 1 except that DURO-TACK (registered trademark) 87-2516 in place of DURO-TACK (registered trademark) 87-4098 was used.
  • Example 13 According to the ratio of blend described in Table 2, the transdermal patches were obtained by a similar manner as Example 9 except that isopropyl myristate was added and the amount of DURO-TACK (registered trademark) 87-202A was changed.
  • DURO-TACK registered trademark
  • Example 14 According to the ratio of blend described in Table 2, the transdermal patches were obtained by a similar manner as Example 9 except that hexadecyl isostearate was added and the amount of DURO-TACK (registered trademark) 87-202A was changed.
  • DURO-TACK registered trademark
  • Example 15 According to the ratio of blend described in Table 2, the transdermal patches were obtained by a similar manner as Example 9 except that dimethylhexadecylamine in place of diisopropanolamine was used.
  • Example 16 According to the ratio of blend described in Table 2, the transdermal patches were obtained by a similar manner as Example 15 except that isopropyl myristate was added and the amounts of riluzole and DURO-TACK (registered trademark) 87-202A were changed.
  • Example 17 According to the ratio of blend described in Table 2, the transdermal patches were obtained by a similar manner as Example 2 except that the amounts of riluzole and DURO-TACK (registered trademark) 87-4098 were changed.
  • Example 18 According to the ratio of blend described in Table 2, the transdermal patches were obtained by a similar manner as Example 9 except that the amounts of riluzole and DURO-TACK (registered trademark) 87-202A were changed.
  • aqueous solution of 40% polyethyleneglycol 400 was used as a receptor solution, and the amounts of riluzole transferred to the receptor solution were determined by HPLC.
  • the fluxes were calculated from the slopes of the regression lines obtained by least-squares method based on the cumulative amounts of permeated riluzole obtained from the experimental results and sampling times. Further, as to the patches of Example 1, Example 2, Example 4, Example 13, Example 16 and Example 17, the delay times were calculated from the time intercepts of the regression lines in order to calculate the plasma concentrations in human by employing a SKIN-CAD (registered trademark, Professional Edition ver.
  • SKIN-CAD registered trademark, Professional Edition ver.
  • the fluxes of the patches of Examples 1 to 18 were 60 to Example 6, Example 7, Example 8, Example 9, Example 10, Example 11, Example 13, Example 14 and Example 15 exhibited increased skin-permeabilities by the skin-penetration enhancers.
  • the effective plasma concentrations required for the patches of the present invention were set to be 40 to 300 ng/mL. As shown in Figures 1 and 2, all of patches of Example 1, Example 2, Example 4, Example 13, Example 16 and Example 17 exhibited the plasma concentrations of 40 to 300 ng/mL.
  • riluzole-containing transdermal patches which maintain the stably effective plasma concentration could be obtained by containing 20 to 60 %, preferably 30 to 60% by weight of riluzole based on the drug-containing layer and setting the area of 15 to 60 cm 2 .
  • the transdermal patches of the present invention are novel patches containing high concentration of riluzole and being able to administer transdermally and quantitatively the drug.
  • the therapeutically effective amount of riluzole can be transdermally and easily administered to the ALS patients having difficulties taking the drug orally.
  • the transdermal patches of the present invention can prevent the occurrence of adverse effects which have become trouble in the oral administration, and the compliance and quality of life (QOL) of the patients can be improved and various problems can be solved, then the transdermal patches of the present invention are useful for the treatment of ALS.

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides a novel transdermal patch containing high concentration of riluzole and being able to administer transdermally and quantitatively the drug to the ALS patients having difficulties taking the drug orally. Furthermore, the transdermal patch of the present invention can prevent adverse effects which have become problem in the oral administration and improved the compliance and quality of life (QOL) of the patients and various problems can be solved, then the transdermal patch of the present invention are useful for the treatment of ALS. Preferably, such patch provided by the present invention contains 20 to 60% by weight of riluzole based on the drug-containing layer and the area of the patch is 15 to 60 cm2.

Description

RILUZOLE-CONTAINING TRANSDERMAL PATCH
This invention relates to a transdermal patch comprising a backing layer, a drug-containing layer and a release liner, and containing riluzole in the drug-containing layer as an active ingredient.
Amyotrophic lateral sclerosis, hereinafter referred to as ALS, is a disease of ventral horn motor neuron and cortex neuron which provides afferent inputs, and is known as the fatal disease by causing pneumonia or respiratory insufficiency to many patients in two to three years. The currently available and sole cure for ALS is an oral drug under the name of "Rilutek (registered trademark) tablet" containing riluzole as an active ingredient.
Since swallowing disturbance and respiratory difficulty are caused in the patients suffered from the advanced ALS symptom, the oral administration to such patients is difficult. Further, rapid increase of the plasma concentration is observed in a short time of period after oral administration of the drug, and more than necessary concentration of the drug is attained temporarily. Due to the excess increase of the plasma concentration of the drug, the occurrence of adverse effects such as symptoms of neuron (helplessness or dizziness) or digestive symptoms (nausea, vomiting or diarrhea) have become problem.
Patent Literature 1 discloses a composition containing riluzole such as cream for the production of a drug for the treatment of the diseases characterized by the hyperproliferation of keratinocytes, particularly psoriasis and atopic dermatitis. This Patent Literature 1 discloses that the cream is a transdermal formulation for the topical administration of riluzole on the skin and the like, and is useful for the treatment and/or prevention of other diseases such as ALS where high plasma concentration is necessary. Though it is needed that an appropriate amount of riluzole should be transdermally administered in consideration of the occurrence of the adverse effects in case that the drugs are administered to the ALS patients for the treatment of ALS, the control of the dose and the plasma concentration by the cream are difficult. While the dosage forms other than the cream are also exemplified in the Patent Literature 1, the patent literature does not disclose the detailed composition and the effectiveness for the ALS treatment. Therefore, the development of the novel transdermal formulation containing riluzole which is useful for ALS treatment has been desired.
WO2004/096216
The object of the present invention is to provide a new transdermal formulation containing riluzole which is capable of the administration to the patients who have difficulties with the oral administration, and is able to inhibit the adverse effects caused by the oral administration and to improve the difficulty of the control of the dose and the plasma concentration caused by the cream described in Patent Literature 1. Furthermore, the another object of the present invention is to provide the transdermal formulation by which high transdermal absorption of riluzole can be achieved and the compliance and quality of life (QOL) of the patients can be improved.
As a result of the repeated intensive investigations to solve the above-mentioned problems, the present inventors have found that providing the transdermal patch containing riluzole can solve the above-mentioned problems and have completed the present invention.
Namely, the present invention relates to the transdermal patch comprising a backing layer, a drug-containing layer and a release liner, and containing riluzole in the drug-containing layer as the active ingredient.
According to the present invention, transdermal patches are adopted as the dosage form of riluzole and these patches are adhered on the skin of the ALS patients, and thereby the transdermal administration of riluzole can be achieved to the ALS patients who have difficulties taking the drug orally. Further, the advantage of the transdermal patches of the present invention can be illustrated that the administration amount of riluzole and the plasma concentration can be controlled, and moreover when the undesired effects have occurred, the administration can be immediately discontinued by removing the patches. Consequently, the transdermal patches of the present invention are superior in view of the safety.
Fig. 1 is a graph exhibiting the human plasma concentration profiles of riluzole of the patches of Examples 1, 2 and 4 which are calculated by using SKIN-CAD (registered trademark), simulation software for the transdermal system. Fig. 2 is a graph exhibiting the human plasma concentration profiles of riluzole of the patches of Examples13, 16 and 17 which are calculated by using SKIN-CAD (registered trademark), simulation software for the transdermal system.
The transdermal patches of the present invention comprise of the drug-containing layer on the backing layer and the drug-containing layer contains riluzole as the active ingredient. Further, a release liner is coated on the drug-containing layer for the purpose of the protection of the drug-containing layer till it uses.
It is important that the transdermal patches of the present invention contain a high concentration of riluzole in the drug-containing layer in order that the effective amount of riluzole for the treatment of ALS is administered transdermally to ALS patients.
In the specification of the present invention, it is meant that the transdermal patch is a medicated adhesive patch that is placed on the skin to deliver a specific dose of drug through the skin and into the bloodstream.
The amount of riluzole of the transdermal patches of the present invention ranges from 20 to 60% by weight based on the drug-containing layer, preferably from 30 to 60% by weight. The case that the amount is less than 20% by weight is not preferable because the effective plasma concentration is not achieved, and the case that the amount is more than 60% by weight is not preferable because the physical or mechanical properties of the patches difficultly maintain satisfactory.
Riluzole which is contained in the transdermal patches of the present invention can be used as a pharmaceutically acceptable salt thereof. The pharmaceutically acceptable salts of riluzole include acid addition salts with inorganic acids or organic acids, and are exemplified, but not limited to, hydrochloride, hydrobromide, nitrate, phosphate, sulfate, acetate, ascorbate, benzoate, cinnamate, citrate, formate, fumarate, glutamate, lactate, maleate, malate, malonate, mandelate, methanesulfonate (mesylate), phthalate, salicylate, stearate, succinate, tartarate, propionate, butyrate, pamoate, p-toluenesulfonate (tosylate) and the like. In performing the present invention, it is preferable to use riluzole in the free form.
The area of the transdermal patches of the present invention may ranges from 15 to 60 cm2. The case when the area is less than 15 cm2 is not preferable because the effective plasma concentration is not attained and the case when the area is more than 60 cm2 is not preferable since the patients feel uncomfortably during the administration and the compliance of the patients is lowered.
The transdermal patches of the present invention comprise the backing layer, the drug-containing layer and the release liner. The release-control membranes to control the transdermal absorption of riluzole or the adhesive layers to adhere to the skin can be added, if desired. Furthermore, the reservoir-type patches can be adopted.
In the transdermal patches of the present invention, the drug-containing layer preferably is a matrix-type adhesive layer containing riluzole and an adhesive agent as a base agent. By providing the patches of the present invention as the matrix-type patches, the patches can be easily designed and the additional layer such as the adhesive layers is not needed so that the cost for manufacturing the patches can be reduced.
The adhesive agents contained in the drug-containing layers of the transdermal patches of the present invention are preferably the non-aqueous adhesive agents, and are inclusive of rubber adhesive agents, acryl polymers and silicone polymers.
The rubber adhesive agents are inclusive of one or not less than two agents selected from styrene-isoprene-styrene block copolymer, styrene-butadiene-styrene block copolymer, styrene-butadiene rubber, polyisobutylene, polybutene, butyl rubber, natural rubber and isoprene rubber and can be used in the present invention.
The acryl polymers include, but not limited to, the polymers or copolymers containing at least one kind of the (meth)acrylate represented by 2-ethylhexyl acrylate, methyl acrylate, butyl acrylate, 2-hydroxyethyl acrylate, 2-ethylhexyl methacrylate and the like as a monomer unit, for example, adhesive polymers such as acrylic acid-octyl acetate copolymer, 2-ethylhexyl acrylate-N-vinyl-2-pyrrolidone-1,6-hexaneglycolyl dimethacrylate copolymer, 2-ethylhexyl acrylate-vinyl acetate copolymer, 2-ethylhexyl acrylate-vinyl acetate-acrylic acid copolymer, 2-ethylhexyl acrylate-2-ethylhexyl methacrylate-dodecyl methacrylate copolymer, methyl methacrylate-2-ethylhexyl acrylate copolymerization resin emulsion, acryl polymer contained in acryl resin-alkanolamine solution can be used and the commercially available DURO-TAK (registered trademark) acrylate adhesive agents series (provided by Henkle Japan Ltd.), GELVA (registered trademark) acrylate adhesive agents series (provided by Monsanto Co.), SK-DYNE MATRIDERM (provided by Soken Chemical and Engineering Co., Ltd) or EUDRAGIT (registered trademark) series (provided by Higuchi Inc.) and can be used in the present invention.
The silicone polymers include derivatives of polysiloxane (for example, silicone polymer such as polydimethylsiloxane and amine-resistant polydimethylsiloxane).
The amount of the adhesive agents added in the drug-containing layer ranges from 20 to 80% by weight, preferably from 35 to 75% by weight in consideration of the formation of the drug-containing layer and the sufficient drug flux. The case when the amount is less than 20% by weight is not preferable because the physical and mechanical properties are hardly maintained well and the case when the amount is more than 80% by weight is not preferable because the effective plasma concentration of riluzole can not be obtained.
One kind, or two or more kinds in combination selected from the above-mentioned rubber adhesive agents, acryl polymers and silicone polymers can be used as the adhesive agents which are contained in the drug-containing layer of the transdermal patches of the present invention. The acryl polymer can be preferably used in view that riluzole can be contained in a high concentration, and further the high concentration of riluzole can exist in a dissolved state in the drug-containing layer. A non-dissolved riluzole, namely crystalline riluzole which is contained or formed in the drug-containing layer is not preferable because it may cause many troubles such as a drop of the flux of riluzole and an increased formation of the crystalline riluzole with a passage of time.
Furthermore, in order to improve the transdermal permeability of riluzole, a skin-penetration enhancer can be added, if necessary. The skin-penetration enhancers are inclusive of any agents exhibiting skin-penetration enhancing effects which are conventionally used, and are exemplified an alkanolamine such as diisopropanolamine and triisopropanolamine; a fatty acid or an ester thereof such as lauric acid, oleic acid, isopropyl myristate, octyldodecyl myristate, glycerin monooleate and hexadecyl isostearate; an alcohol, an ester thereof or an ether thereof such as oleyl alcohol, propyleneglycol and polyethyleneglycol monooleate; a sorbitan ester or ether such as sorbitan monolaurate and sorbitan monooleate; a phenol ether such as polyoxyethylene nonylphenyl ether or polyoxyethylene octylphenyl ether; castor oil or hydrogenated castor oil; an ionic surfactant such as oleoylsarcosine, lauryldimethylaminoacetic acid betaine and sodium laurylsulfate; a non-ionic surfactant such as polyoxyethylene oleyl ether, polyoxyethylene lauryl ether and dimethyllaurylamine oxide; an alkylmethylsulfoxide such as dimethylsulfoxide and decylmethylsulfoxide; a pyrrolidone such as 2-pyrrolidone and 1-methyl-2-pyrrolidone; an azacycloalkane such as 1-dodecylazacycloheptan-2-one and 1-geranylazacycloheptan-2-one; or a terpene such as menthol, camphor and limonene. Among them, an alkanolamine such as diisopropanolamine and triisopropanolamine; a myristic acid ester such as isopropyl myristate, octyldodecyl myristate or hexadecyl isostearate; propyleneglycol; polyoxyethylene lauryl ether or polyoxyethylene oleyl ether are preferable.
In case that the skin-penetration enhancer is added to the transdermal patches of the present invention, the amount of the skin-penetration enhancer may ranges from 0.1 to 10% by weight, preferably from 1 to 5% by weight based on the drug-containing layer. Moreover, the contents which exceed 10% by weight are not preferable since the skin irritation caused by the skin-penetration enhancers is used to develop and further the physical properties of the patches are lowered and sticky sense is generated.
An additional agent such as a plasticizer, an antioxidant, a cross-linker, a colorant, an ultraviolet ray absorbent, or a tackifier and the like can be blended to the transdermal patches of the present invention, if necessary.
The plasticizers include a petroleum oil such as paraffinic process oil, naphthenic process oil and aromatic process oil; a liquid fatty acid ester such as isopropyl myristate, hexyl laurate, diethyl sebacate, diisopropyl sebacate and isopropyl linoleate; a plant oil such as olive oil, camellia oil, castor oil, tall oil and peanut oil; glycerin; chlorobutanol; polyvinyl acetate; dimethylpolysiloxane-silicon dioxide mixture; d-sorbitol; medium chain fatty acid triglyceride; triacetin; 2-pyrrolidone; phytosterol; propylene glycol; polyethylene glycol; polysorbate 80 (registered trademark); and glyceryl monostearate.
The antioxidants include ascorbic acid, sodium bisulfite, sodium pyrosulfite, disodium edetate, citric acid, potassium dichloroisocyanurate, dibutylhydroxytoluene, soybean lecithin, thymol, tocopherol or ester thereof, ascorbic acid palmitate, butylhydroxyanisol, 1,3-butylene glycol, benzotriazole, pentaerythrityl-tetrakis[3-(3,5- di-t-butyl-4-hydroxyphenyl)propionate], monothioglycerol, and propyl gallate.
The cross-linkers include amino resin; phenolic resin; epoxy resin; alkyd resin; a thermosetting resin such as unsaturated polyester; isocyanate compound; organic cross-linker; and an inorganic cross-linker such as metal or metal compound.
The colorants include indigocarmine, yellow oxide of iron, yellow ferric oxide, carbon black, caramel, photosensitizer 201, sasa albo-marginata extract, black iron oxide, kekketsu, zinc oxide, titanium oxide, red ferric oxide, amaranth, sodium hydroxide, talc, sodium copper chlorophyllin, rye green leaf juice powder, d-borneol, 2-octyldodecyl myristate, methylrosanilinium chloride, methylene blue, ammonium manganese phosphate, and rose oil.
The ultraviolet ray absorbents include an amino acid compound such as urocanic acid; a benzophenone compound such as 2,4-dihydroxybenzophenone and 2-hydroxy-4-n-octoxybenzophenone; a cinnamic acid derivative such as cinoxate and diethanolamine-p-methoxycinnamate; a cyanoacrylate derivative such as 2-ethylhexyl-2-cyano-3,3-diphenylacrylate; an aminobenzoic acid derivative such as ethyl p-aminobenzoate and propyl p-aminobenzoate; an anthranilic acid derivative such as anthranilic acid and menthyl anthranilate; a salicylate derivative such as phenyl salicylate and p-octylphenyl salicylate; and a coumarin derivative such as 7-ethylamino-4-methylcoumarin and 7,8-dihydroxy coumarin.
The tackifiers include a rosin derivative such as rosin, glycerol ester of rosin, hydrogenated rosin and glycerol ester of hydrogenated rosin; alicyclic saturated hydrocarbon resin; alicyclic hydrocarbon resin; terpene resin; aliphatic saturated hydrocarbon resin; aliphatic hydrocarbon resin; maleic acid resin; carnauba wax; carmellose sodium; xanthan gum; chitosan; glycerin; aluminum magnesium silicate; light anhydrous silicic acid; benzyl acetate; talc; hydroxyethylcellulose; hydroxypropylcellulose; hypromellose; polyacrylic acid; sodium polyacrylate; partially neutralized polyacrylate; and polyvinyl alcohol.
The drug-impermeable elastic or non-elastic backing can be used as the backing of the transdermal patches of the present invention. Such backings include, for example, synthetic resin film or sheet such as polyethylene, polypropylene, polybutadiene, ethylene vinyl acetate copolymer, polyvinyl chloride, polyester (e.g. polyethylene terephthalate), nylon, polyurethane, or laminates thereof, porous materials and foam thereof, paper, textiles and nonwovens and the like.
As the release liner of the transdermal patches of the present invention, the drug-impermeable release liner can be used. Such liners are, for example, inclusive of films made of polymer such as polyethylene, polypropylene and polyester and the like, aluminum evaporated film, silicone oil and the like applied paper and the like. Among them, polyester film is preferable and polyethylene terephthalate (PET) film is more preferable in view of impermeability of the drug, processability and low cost and the like. Furthermore, laminate films laminated by multiple materials can be used as such release liner.
The transdermal patches of the present invention can be prepared, but not limited to, by the known methods. The preferable known methods for preparing the transdermal patches of the present invention include, for example, the method for obtaining the transdermal patches by dissolving the agents such as riluzole and the adhesive polymers and, if necessary, the skin-penetration enhancer to be added to the drug-containing layer into an organic solvent such as ethyl acetate, hexane, toluene or a mixture thereof, spreading these dissolved materials on the release liner or the backing, and evaporating the solvent in the dissolved materials to form the drug-containing layer and thereafter coating on the backing or the release liner, or the method for obtaining the transdermal patches by heating and melting the agents such as riluzole and the adhesive polymers and, if necessary, the skin-penetration enhancer to be added to the drug-containing layer, spreading the melted materials on the release liner or the backing to form the drug-containing layer and thereafter coating on the backing or the release liner.
The present invention is explained in more detail by the following examples and it is construed that the present invention is not limited thereto.
Example 1
According to the ratio of blend described in Table 1, to an acrylic polymer (DURO-TACK (registered trademark) 87-4098, available from Henkle Japan Ltd.) riluzole was added, and mixed with stirring to obtain the homogeneous dissolved mixture. Then the homogeneous dissolved mixture was spreaded on a release liner (silicone-treated PET film, available from Fujimori Kogyo Co., Ltd.) to
Figure JPOXMLDOC01-appb-I000001
and the solvent was distilled off to form the drug-containing layer and then the backing was coated. Then, the transdermal patches were obtained by cutting into an appropriate size.
Example 2
According to the ratio of blend described in Table 1, to an acrylic polymer (DURO-TACK (registered trademark) 87-4098), riluzole and diisopropanolamine were added, and mixed with stirring to obtain the homogeneous dissolved mixture. Then the homogeneous dissolved mixture was spreaded on a release liner (silicone-treated PET
Figure JPOXMLDOC01-appb-I000002
containing material after distilling off the solvent by using a doctor blade coater, and the solvent was distilled off to form the drug-containing layer and then the backing was coated. Then, the transdermal patches were obtained by cutting into an appropriate size.
Example 3
According to the ratio of blend described in Table 1, the transdermal patches were obtained by a similar manner as Example 2 except that triisopropanolamine in place of diisopropanolamine was used.
Example 4
According to the ratio of blend described in Table 1, the transdermal patches were obtained by a similar manner as Example 2 except that propyleneglycol in place of diisopropanolamine was used.
Example 5
According to the ratio of blend described in Table 1, the transdermal patches were obtained by a similar manner as Example 2 except that isopropyl myristate in place of diisopropanolamine was used.
Example 6
According to the ratio of blend described in Table 1, the transdermal patches were obtained by a similar manner as Example 2 except that octyldodecyl myristate in place of diisopropanolamine was used.
Example 7
According to the ratio of blend described in Table 1, the transdermal patches were obtained by a similar manner as Example 2 except that polyoxyethylene lauryl ether in place of diisopropanolamine was used.
Example 8
According to the ratio of blend described in Table 1, the transdermal patches were obtained by a similar manner as Example 2 except that polyoxyethylene oleyl ether in place of diisopropanolamine was used.
Example 9
According to the ratio of blend described in Table 1, the transdermal patches were obtained by a similar manner as Example 2 except that DURO-TACK (registered trademark) 87-202A (available from Henkle Japan Ltd.) in place of DURO-TACK (registered trademark) 87-4098 was used.
Example 10
According to the ratio of blend described in Table 1, the transdermal patches were obtained by a similar manner as Example 2 except that DURO-TACK (registered trademark) 87-2100 (available from Henkle Japan Ltd.) in place of DURO-TACK (registered trademark) 87-4098 was used.
Example 11
According to the ratio of blend described in Table 2, the transdermal patches were obtained by a similar manner as Example 2 except that DURO-TACK (registered trademark) 87-2516 (available from Henkle Japan Ltd.) in place of DURO-TACK (registered trademark) 87-4098 was used.
Example 12
According to the ratio of blend described in Table 2, the transdermal patches were obtained by a similar manner as Example 1 except that DURO-TACK (registered trademark) 87-2516 in place of DURO-TACK (registered trademark) 87-4098 was used.
Example 13
According to the ratio of blend described in Table 2, the transdermal patches were obtained by a similar manner as Example 9 except that isopropyl myristate was added and the amount of DURO-TACK (registered trademark) 87-202A was changed.
Example 14
According to the ratio of blend described in Table 2, the transdermal patches were obtained by a similar manner as Example 9 except that hexadecyl isostearate was added and the amount of DURO-TACK (registered trademark) 87-202A was changed.
Example 15
According to the ratio of blend described in Table 2, the transdermal patches were obtained by a similar manner as Example 9 except that dimethylhexadecylamine in place of diisopropanolamine was used.
Example 16
According to the ratio of blend described in Table 2, the transdermal patches were obtained by a similar manner as Example 15 except that isopropyl myristate was added and the amounts of riluzole and DURO-TACK (registered trademark) 87-202A were changed.
Example 17
According to the ratio of blend described in Table 2, the transdermal patches were obtained by a similar manner as Example 2 except that the amounts of riluzole and DURO-TACK (registered trademark) 87-4098 were changed.
Example 18
According to the ratio of blend described in Table 2, the transdermal patches were obtained by a similar manner as Example 9 except that the amounts of riluzole and DURO-TACK (registered trademark) 87-202A were changed.
Figure JPOXMLDOC01-appb-T000001
Figure JPOXMLDOC01-appb-T000002
Experimental Example 1
Experiments on skin permeability of the drug:
The skin permeability of riluzole from the transdermal patches of Examples 1 to 18 prepared by the above-mentioned formulations and methods was examined by using the cell for the membrane permeation. Skins (intact skins) isolated from the back of hairless mice (n=4 to 6, Hr-/Kud, Kyudo Co., Ltd.) were attached to the cell for the membrane permeation, the patches of each examples were applied on the side of stratum corneum of the skins, and then applied to an in-vitro membrane-permeation test instruments. An aqueous solution of 40% polyethyleneglycol 400 was used as a receptor solution, and the amounts of riluzole transferred to the receptor solution were determined by HPLC. The fluxes were calculated from the slopes of the regression lines obtained by least-squares method based on the cumulative amounts of permeated riluzole obtained from the experimental results and sampling times. Further, as to the patches of Example 1, Example 2, Example 4, Example 13, Example 16 and Example 17, the delay times were calculated from the time intercepts of the regression lines in order to calculate the plasma concentrations in human by employing a SKIN-CAD (registered trademark, Professional Edition ver. 5.2 available from i-HIVE Communication, Inc.), a simulation software for the transdermal system, and also the similar experiments were performed by using the exfoliated skins(strip skins) from the stratum corneums of the isolated skins from the back of hairless mice with cellophane tape. The results are summarized in Table 3.
Figure JPOXMLDOC01-appb-T000003
 In this Table 3, "-" means "not-tested".
As shown in Table 3, the fluxes of the patches of Examples 1 to 18 were 60 to
Figure JPOXMLDOC01-appb-I000003
Example 6, Example 7, Example 8, Example 9, Example 10, Example 11, Example 13, Example 14 and Example 15 exhibited increased skin-permeabilities by the skin-penetration enhancers.
Experimental Example 2
Human plasma concentrations by the continuous administration at the interval of 24 hours were calculated by employing a SKIN-CAD (registered trademark, Professional Edition ver. 5.2 available from i-HIVE Communication, Inc.), the simulation software for the transdermal system based on the pharmacokinetic parameters of riluzole in human and the parameters (Table 3) obtained from the results of skin-permeability experiments by employing hairless mice for the patches of Example 1, Example 2, Example 4, Example 13, Example 16 and Example 17. The results were summarized in Figures 1 and 2. The areas of the patches of Example 1, Example 2, Example 4, Example 13 and Example 16 were set to 60 cm2, and the area of the patch of Example 17 was set to 15 cm2.
Based on that the plasma concentrations at the steady state by the repeated administration of the oral preparation of 50 mg of riluzole is about 40 (minimum) to about 300 (maximum) ng/mL (cf. "Journal of Clinical Therapeutics & Medicine", vol. 12, No. 5, pp. 809(61)-827(79), 1996; especially Fig. 5 and Table 6), the effective plasma concentrations required for the patches of the present invention were set to be 40 to 300 ng/mL. As shown in Figures 1 and 2, all of patches of Example 1, Example 2, Example 4, Example 13, Example 16 and Example 17 exhibited the plasma concentrations of 40 to 300 ng/mL. These results demonstrated that the riluzole-containing transdermal patches which maintain the stably effective plasma concentration could be obtained by containing 20 to 60 %, preferably 30 to 60% by weight of riluzole based on the drug-containing layer and setting the area of 15 to 60 cm2.
As mentioned above, the transdermal patches of the present invention are novel patches containing high concentration of riluzole and being able to administer transdermally and quantitatively the drug. According to the transdermal patches of the present invention, the therapeutically effective amount of riluzole can be transdermally and easily administered to the ALS patients having difficulties taking the drug orally. Furthermore, the transdermal patches of the present invention can prevent the occurrence of adverse effects which have become trouble in the oral administration, and the compliance and quality of life (QOL) of the patients can be improved and various problems can be solved, then the transdermal patches of the present invention are useful for the treatment of ALS.

Claims (16)

  1. In a transdermal patch comprising a backing, a drug-containing layer and a release liner, riluzole is contained in the drug-containing layer as an active ingredient.
  2. The transdermal patch of Claim 1, wherein said patch are useful for the treatment of amyotrophic lateral sclerosis.
  3. The transdermal patch of Claim 1 or Claim 2, wherein said patch contains the effective amount of riluzole for the treatment of amyotrophic lateral sclerosis.
  4. The transdermal patch of any of Claim 1 to Claim 3, wherein said patch contains 20 to 60% by weight of riluzole based on the drug-containing layer.
  5. The transdermal patch of any of Claim 1 to Claim 3, wherein said patch contains 30 to 60% by weight of riluzole based on the drug-containing layer.
  6. The transdermal patch of any of Claim 1 to Claim 5, wherein the area of said patch is 15 to 60 cm2.
  7. The transdermal patch of any of Claim 1 to Claim 6, wherein the drug-containing layer is a matrix-type adhesive layer containing a base agent and riluzole.
  8. The transdermal patch of Claim 7, wherein said patch contains one or more than two adhesive base agents selected from rubber adhesives, acrylate polymers and silicone polymers as the base agent of the matrix-type adhesive layer.
  9. The transdermal patch of Claim 7, wherein said patch contains acrylate polymers as the base agent of the matrix-type adhesive layer.
  10. The transdermal patch of any of Claim 1 to Claim 9, wherein the drug-containing layer contains a skin-penetration enhancer.
  11. The transdermal patch of Claim 10, wherein the drug-containing layer contains 0.1 to 10% by weight of the skin-penetration enhancer based on the drug-containing layer.
  12. The transdermal patch of Claim 10, wherein the drug-containing layer contains 1 to 5% by weight of the skin-penetration enhancer based on the drug-containing layer.
  13. The transdermal patch of any of Claim 10 to Claim 12, wherein the skin-penetration enhancers are at least one selected from an alkanolamine, an ester of myristic acid, hexadecyl isostearate, propylene glycol, polyoxyethylene lauryl ether and polyoxyethylene oleyl ether.
  14. The transdermal patch of Claim 13, wherein the alkanolamine is diisopropanolamine and/or triisopropanolamine.
  15. The transdermal patch of Claim 13, wherein the ester of myristic acid is isopropyl myristate and/or octyldodecyl myristate.
  16. The transdermal patch of any of Claim 1 to Claim 15, wherein said patch is free from the crystalline riluzole.
PCT/JP2009/004320 2009-03-30 2009-09-02 Riluzole-containing transdermal patch WO2010113225A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009083348 2009-03-30
JP2009-083348 2009-03-30

Publications (1)

Publication Number Publication Date
WO2010113225A1 true WO2010113225A1 (en) 2010-10-07

Family

ID=42827558

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2009/004320 WO2010113225A1 (en) 2009-03-30 2009-09-02 Riluzole-containing transdermal patch

Country Status (1)

Country Link
WO (1) WO2010113225A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2570116A1 (en) * 2011-09-13 2013-03-20 Nitto Denko Corporation Composition for enhancing transdermal absorption of a drug and patch preparation
EP2570115A1 (en) * 2011-09-13 2013-03-20 Nitto Denko Corporation Composition for enhancing transdermal absorption of a drug and patch preparation
EP2865376A4 (en) * 2012-06-20 2015-11-18 Medrx Co Ltd Adhesive preparation composition obtained by blending drug, organic solvent, lipophilic ointment base, and powder
US9980920B2 (en) 2013-09-11 2018-05-29 Medrx Co., Ltd. Base composition for tape agent

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000281566A (en) * 1999-01-28 2000-10-10 Yuutoku Yakuhin Kogyo Kk Improved time control system for drug releasing of percutaneous preparation
WO2000074676A1 (en) * 1999-06-04 2000-12-14 Vereniging Voor Christelijk Wetenschappelikjk Onderwijs Use of riluzole for the treatment of multiple sclerosis
JP2002539162A (en) * 1999-03-12 2002-11-19 アベンテイス・フアルマ・ソシエテ・アノニム Treatment of amyotrophic lateral sclerosis using a combination of riluzole and AMPA receptor antagonist
JP2003104874A (en) * 2001-09-28 2003-04-09 Yuutoku Yakuhin Kogyo Kk Device for release controlling medicine
JP2003183156A (en) * 2001-12-21 2003-07-03 Yuutoku Yakuhin Kogyo Kk Patch preparation for external use

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000281566A (en) * 1999-01-28 2000-10-10 Yuutoku Yakuhin Kogyo Kk Improved time control system for drug releasing of percutaneous preparation
JP2002539162A (en) * 1999-03-12 2002-11-19 アベンテイス・フアルマ・ソシエテ・アノニム Treatment of amyotrophic lateral sclerosis using a combination of riluzole and AMPA receptor antagonist
WO2000074676A1 (en) * 1999-06-04 2000-12-14 Vereniging Voor Christelijk Wetenschappelikjk Onderwijs Use of riluzole for the treatment of multiple sclerosis
JP2003104874A (en) * 2001-09-28 2003-04-09 Yuutoku Yakuhin Kogyo Kk Device for release controlling medicine
JP2003183156A (en) * 2001-12-21 2003-07-03 Yuutoku Yakuhin Kogyo Kk Patch preparation for external use

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2570116A1 (en) * 2011-09-13 2013-03-20 Nitto Denko Corporation Composition for enhancing transdermal absorption of a drug and patch preparation
EP2570115A1 (en) * 2011-09-13 2013-03-20 Nitto Denko Corporation Composition for enhancing transdermal absorption of a drug and patch preparation
US9707187B2 (en) 2011-09-13 2017-07-18 Nitto Denko Corporation Composition for enhancing transdermal absorption of a drug and patch preparation
US9707189B2 (en) 2011-09-13 2017-07-18 Nitto Denko Corporation Composition for enhancing transdermal absorption of a drug and patch preparation
EP2865376A4 (en) * 2012-06-20 2015-11-18 Medrx Co Ltd Adhesive preparation composition obtained by blending drug, organic solvent, lipophilic ointment base, and powder
AU2013278403B2 (en) * 2012-06-20 2018-02-01 Medrx Co., Ltd. Adhesive preparation composition obtained by blending drug, organic solvent, lipophilic ointment base, and powder
CN108553452A (en) * 2012-06-20 2018-09-21 美德阿利克斯株式会社 The adhesion preparation composition obtained by blending drug, organic solvent, lipophilicity matrix and powder
US10543275B2 (en) 2012-06-20 2020-01-28 Medrx Co., Ltd. Composition for patch preparation comprising drug, organic solvent, lipophilic mass base, and powder
US12016924B2 (en) 2012-06-20 2024-06-25 Medrx Co., Ltd. Composition for patch preparation comprising drug, organic solvent, lipophilic mass base, and powder
US9980920B2 (en) 2013-09-11 2018-05-29 Medrx Co., Ltd. Base composition for tape agent

Similar Documents

Publication Publication Date Title
US20080138388A1 (en) Transdermal Absorption Patch
WO2011049038A1 (en) Transdermally absorbable donepezil-containing preparation
EP1992363B1 (en) Transdermal absorption preparation
EP2654739B1 (en) Percutaneous absorption preparation containing rivastigmine
JP5403948B2 (en) Memantine-containing transdermal absorption preparation
TW201431570A (en) Multi-day patch for the transdermal administration of rotigotine
JP2014177428A (en) Rotigotine percutaneous absorption type patch formulation containing rosin resin
JP5073124B2 (en) Noradrenergic / specific serotonergic antidepressant-containing transdermal absorption patch
JPWO2006080199A1 (en) Patch
WO2010113225A1 (en) Riluzole-containing transdermal patch
WO2014174564A1 (en) Adhesive patch drug formulation of transdermal absorption type containing memantine
WO2016080533A1 (en) Percutaneous absorption agent
WO2005102306A1 (en) Anti-inflammatory analgesic adhesive patch
WO2014199455A1 (en) Percutaneous absorption type patch memantine preparation
JP6729584B2 (en) Transdermal patch
JP6459148B2 (en) Transdermal preparation
WO2018104772A1 (en) Percutaneous absorption-type preparation
JP6675589B2 (en) Transdermal formulation
WO2016208729A1 (en) Nalfurafine-containing percutaneous absorption patch
WO2017057541A1 (en) Transdermal absorption preparation
JP6512905B2 (en) Fentanyl-containing patch
WO2013183407A1 (en) Mirtazapine-containing transdermally-absorbable skin-adhesive preparation
JPWO2005041967A1 (en) Transdermal absorption preparation and method for reducing side effects in pergolide therapy
JP7352283B2 (en) Transdermal absorption preparation containing fentanyl citrate
JP2017007994A (en) Percutaneous absorption-type preparation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09842582

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09842582

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP